Biocept Inc. (NASDAQ: BIOC) Starts Presentation at The LD 500
Biocept Inc. (NASDAQ: BIOC) is a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes. As a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers and melanoma, Biocept leverages its proprietary liquid biopsy technology to provide physicians with data for treating and monitoring patients diagnosed with cancer. The company's patented Target Selector(TM) liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to…







